Lignin nanoparticles as a promising vaccine adjuvant and delivery system for ovalbumin

Lignin nanoparticles as a promising vaccine adjuvant and delivery system for ovalbumin

Vaccination is the most effective strategy of preventing and treating infectious diseases and the most significant issue in the development of potent vaccines is the sufficient immunogenicity and safety of vaccines. The main goal of the present study is to develop a potent and safe vaccine adjuvant...

Full description

Saved in:
Bibliographic Details
Published in:International journal of biological macromolecules Vol. 163; pp. 1314 - 1322
Main Authors: Alqahtani, Mohammed S., Kazi, Mohsin, Ahmad, Muhammad Z., Syed, Rabbani, Alsenaidy, Mohammad A., Albraiki, Salem A.
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 15-11-2020
Subjects:
Adjuvant
Adjuvants, Immunologic - chemistry
Animals
Antigen
Antigens - immunology
Dendritic Cells - immunology
Dendritic Cells - metabolism
Drug Carriers - chemistry
Drug Delivery Systems
Lignin
Lignin - chemistry
Male
Mice
Nanoparticles
Nanoparticles - chemistry
Nanoparticles - ultrastructure
Ovalbumin
Ovalbumin - administration & dosage
Spectroscopy, Fourier Transform Infrared
Vaccine
Vaccines - immunology
Nanoparticles
Antigen
Lignin
Ovalbumin
Adjuvant
Vaccine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vaccination is the most effective strategy of preventing and treating infectious diseases and the most significant issue in the development of potent vaccines is the sufficient immunogenicity and safety of vaccines. The main goal of the present study is to develop a potent and safe vaccine adjuvant that can also stabilize antigen formulations during preparation and storage. In this study, the model antigen ovalbumin (OVA) was encapsulated in polymeric nanoparticles based on lignin (OVA-LNPs). The nanoparticles had a particle size of 216 nm and a low polydispersity index. The nanoparticles were negatively charged (−26.7 mV) with high encapsulation efficiency 81.6% of OVA antigen. In vitro studies of the nanoparticles were tested against dendritic cells (DCs), specialized antigen-presenting cells (APCs). The results showed no cytotoxic effect from LNPs and a significantly higher percentage of dendritic cells have taken up the antigen when encapsulated inside LNPs in contrast to free OVA. The nanoparticle was administered intradermally to BALB/c mice and the resulting time-dependent systemic immune responses towards OVA were assessed by measuring the OVA-specific IgG titers using an enzyme-linked immunosorbent assay (ELISA). In vivo immunization with OVA-LNPs induced a stronger IgG antibody response than that induced by free OVA or alum adjuvanted OVA. Enhanced immunization by OVA-LNPs was attributed to the observed efficient uptake of the antigen by dendritic cells. These findings demonstrate that LNPs are promising to be used as vaccine adjuvant and delivery system for the induction of long-term immune responses.
ISSN:0141-8130
1879-0003
DOI:10.1016/j.ijbiomac.2020.07.026